2 Top Biotech Stocks That Wall Street Thinks Could Soon Double in Value
Analysts on Wall Street have probably spent more time thinking about the price of stocks than you have, because it's their full-time job. That doesn't mean they're always correct, but it does suggest that there's a lot to learn from understanding their estimates and thinking about how they're…#ginkgobioworks #ginkgo #pfizer #novonordisk #merck #iova #nsclc #fda #iovance #alexcarchidi (Source: Reuters: Health)
Source: Reuters: Health - February 23, 2024 Category: Consumer Health News Source Type: news
Osimertinib Plus Chemo Approved for EGFR-mutated NSCLC Osimertinib Plus Chemo Approved for EGFR-mutated NSCLC
With the new approval, patients now have the option of combination treatment or osimertinib monotherapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 22, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Tagrisso With the Addition of Chemotherapy Approved in the US for Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer
19 February 2024 -- AstraZeneca’s Tagrisso has been approved in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC).
The approval... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 19, 2024 Category: Drugs & Pharmacology Source Type: news
Datopotamab Deruxtecan Biologics License Application Accepted in the US for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer
Application based on results from the TROPION-Lung01 Phase III trial
If approved, AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan may be the first TROP2-directed antibody drug conjugate for patients with lung cancer
19 February... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - February 19, 2024 Category: Drugs & Pharmacology Source Type: news
FDA approves osimertinib with chemotherapy for EGFR-mutated non-small cell lung cancer
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 16, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Perioperative Tislelizumab Demonstrates Survival Benefit in NSCLC
(MedPage Today) -- Adding tislelizumab to neoadjuvant chemotherapy followed by adjuvant use of the investigational PD-1 inhibitor improved event-free survival (EFS) in resectable non-small cell lung cancer (NSCLC), a phase III trial from China... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 16, 2024 Category: Hematology Source Type: news
Tepotinib Gains Full Approval for Metastatic NSCLC
(MedPage Today) -- The FDA transitioned the small-molecule inhibitor tepotinib (Tepmetko) from accelerated to full approval for metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping alterations.
The action occurred after... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - February 16, 2024 Category: American Health Source Type: news
FDA Grants Traditional Approval to Tepmetko (tepotinib) for Metastatic Non-Small Cell Lung Cancer
On February 15, 2024, the Food and Drug Administration granted traditional approval to tepotinib (Tepmetko, EMD Serono, Inc.) for adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 15, 2024 Category: Drugs & Pharmacology Source Type: news
FDA approves tepotinib for metastatic non-small cell lung cancer
On February 15, 2024, the Food and Drug Administration granted traditional approval to tepotinib (Tepmetko, EMD Serono, Inc.) for adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 15, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Pembrolizumab Improves Event-Free Survival in Early NSCLC
TUESDAY, Feb. 13, 2024 -- For patients with early-stage non-small cell lung cancer (NSCLC), event-free survival (EFS) is improved with neoadjuvant pembrolizumab and chemotherapy, according to a study presented at the annual meeting of The Society of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 13, 2024 Category: Pharmaceuticals Source Type: news
Is Consolidation Osimertinib Superior in EGFR-Mutated NSCLC? Is Consolidation Osimertinib Superior in EGFR-Mutated NSCLC?
A retrospective study showed consolidated osimertinib after chemoradiation prolonged progression-free survival in patients with EGFR-mutated, stage III NSCLC compared with durvalumab or observation.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 8, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
What's Next for Iovance Biotherapeutics Stock?
Depending on which facts you choose to focus on, you could have widely varying opinions on Iovance Biotherapeutics (NASDAQ: IOVA). From one perspective, it's an ailing biotech that's facing down the specter of serious -- potentially existential -- risks inherent to the focus of its scientific…#iovance #fda #nsclc #alexcarchidi #motleyfool (Source: Reuters: Health)
Source: Reuters: Health - February 5, 2024 Category: Consumer Health News Source Type: news
Toxicity Linked to Longer Survival in Patients With NSCLC Toxicity Linked to Longer Survival in Patients With NSCLC
A new cohort study shows that some immune-related adverse events are linked to longer survival in patients with NSCLC treated with immunotherapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 30, 2024 Category: Consumer Health News Tags: Hematology-Oncology Source Type: news
Gilead Provides Update on Phase 3 EVOKE-01 Study
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival (OS) in previously treated metastatic non-small cell lung cancer (NSCLC). EVOKE-01 is evaluating Trodelvy® (sacituzumab govitecan-hziy; SG) vs. docetaxel in…#gileadsciencesinc #phase3 #nsclc #gilead #trodelvy #merdadparsey #phd #gileadsciences #phase2 #worldconference (Source: Reuters: Health)
Source: Reuters: Health - January 22, 2024 Category: Consumer Health News Source Type: news
Why Is HIV Drug Giant Gilead Stock Trading Lower Today?
Gilead Sciences Inc GILD said its Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival (OS) in previously treated metastatic non-small cell lung cancer (NSCLC). EVOKE-01 is evaluating Trodelvy (sacituzumab govitecan-hziy; SG) vs. docetaxel in patients with metastatic or…#nsclc #trop2 #gild (Source: Reuters: Health)
Source: Reuters: Health - January 22, 2024 Category: Consumer Health News Source Type: news
